



US 20190033297A1

(19) **United States**(12) **Patent Application Publication**
ADZHUBEI et al.(10) **Pub. No.: US 2019/0033297 A1**(43) **Pub. Date: Jan. 31, 2019**(54) **COMPOUNDS INHIBITING NEF-CALNEXIN
INTERACTION**(71) Applicants: **Alexei ADZHUBEI**, Moscow (RU);
**THE GEORGE WASHINGTON
UNIVERSITY, A
CONGRESSIONALLY
CHARTERED NOT-FOR-PROFIT
CORPORATI**, Washington, DC (US)(72) Inventors: **Alexei ADZHUBEI**, Moscow (RU);
Michael BUKRINSKY, Potomac, MD
(US); **Ruth HUNEGNAW**, Arlington,
VA (US)(73) Assignees: **THE GEORGE WASHINGTON
UNIVERSITY, A
CONGRESSIONALLY
CHARTERED NOT-FOR-PROFIT;
CORPORATION**, Washington, DC
(US)(21) Appl. No.: **16/069,483**(22) PCT Filed: **Jan. 12, 2017**(86) PCT No.: **PCT/US2017/013236**

§ 371 (c)(1),

(2) Date: **Jul. 11, 2018****Related U.S. Application Data**(60) Provisional application No. 62/277,720, filed on Jan.
12, 2016.**Publication Classification**(51) **Int. Cl.****G01N 33/50** (2006.01)**C07C 223/06** (2006.01)**C07D 209/56** (2006.01)**C07C 381/00** (2006.01)(52) **U.S. Cl.**CPC **G01N 33/5041** (2013.01); **C07C 223/06**
(2013.01); **G01N 2333/4727** (2013.01); **C07C**
381/00 (2013.01); **G01N 2333/163** (2013.01);
C07D 209/56 (2013.01)(57) **ABSTRACT**

The invention relates to compounds and methods for restoring or preserving cholesterol efflux in a cell infected with Human Immunodeficiency Virus (HIV) by preventing or decreasing an interaction between Negative Regulatory Factor (Nef) protein and Calnexin protein, and methods for screening for such compounds.